TAKHZYRO 300 mg/2mL
lanadelumab-flyo · INJECTION, SOLUTION · Takeda Pharmaceuticals America, Inc.
TAKHZYRO is a injection, solution containing lanadelumab-flyo at 300 mg/2mL, taken subcutaneous. Manufactured by Takeda Pharmaceuticals America, Inc..
Key Facts
- Brand Name
- TAKHZYRO
- Generic Name
- lanadelumab-flyo
- NDC Code (Product)
47783-644- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Strength
- 300 mg/2mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761090
- Drug Class
- Plasma Kallikrein Inhibitor [EPC]
- Marketing Start
- 08/24/2018
Recall History
No Recall HistoryFrequently Asked Questions
What is TAKHZYRO used for?
TAKHZYRO contains lanadelumab-flyo. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is TAKHZYRO a controlled substance?
TAKHZYRO is not classified as a controlled substance by the DEA.
What is the generic name for TAKHZYRO?
The generic name for TAKHZYRO is lanadelumab-flyo. There are no other listed brand versions of lanadelumab-flyo.
What is the NDC code for TAKHZYRO 300 mg/2mL?
The NDC (National Drug Code) for TAKHZYRO 300 mg/2mL is 47783-644, listed by Takeda Pharmaceuticals America, Inc..
Other TAKHZYRO Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)